Literature DB >> 27822424

Nuclear TBLR1 as an ER corepressor promotes cell proliferation, migration and invasion in breast and ovarian cancer.

Xinyu Wu1, Yang Zhan2, Xin Li3, Jianjun Wei4, Larion Santiago1, Garrett Daniels1, Fangming Deng1, Xuelin Zhong1, Luis Chiriboga1, Ross Basch1, Sheng Xiong1, Yan Dong2, Xinmin Zhang5, Peng Lee6.   

Abstract

Estrogen receptors (ER) play important roles in the development and progression of breast and ovarian cancers. ERs mediate transcriptional regulation through interaction with cofactors and binding to response elements within the regulatory elements of target genes. Here, we examined the expression and function of TBLR1/TBL1XR1, a core component of NCoR (nuclear receptor corepressor) and SMRT (silencing mediator of retinoic acid and thyroid receptor) corepressor complexes, in breast and ovarian cancers. We found that although TBLR1 is present in both the nucleus and cytoplasm of normal and neoplastic breast and ovarian cells, it is expressed at significantly higher levels in the nucleus of malignant breast and ovarian cells compared to benign cells. TBLR1 functions as an ER corepressor to inhibit ER-mediated transcriptional activation in both breast and ovarian cell lines, but it has no effect on androgen receptor (AR) mediated transcriptional activation in these cells. Furthermore, ectopic expression of nuclear TBLR1 in breast and ovarian cancer cells stimulates cell proliferation. The increased cell proliferation by nuclear TBLR1 is through both ER-independent and ER-dependent mechanisms as evidenced by increased growth in hormone-free medium and estrogen medium, as well as reduced growth with ER knockdown by siRNA. Nuclear TBLR1 overexpression also increased migration and invasion in both breast and ovarian cancer cells. Determining the functional relationship between TBLR1 and ER may provide insights to develop novel treatment strategies and improve response to hormonal therapy in breast and ovarian cancers.

Entities:  

Keywords:  Breast cancer; TBL1XR1; estrogen receptor; nuclear TBLR1; ovarian cancer

Year:  2016        PMID: 27822424      PMCID: PMC5088298     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  19 in total

1.  Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1.

Authors:  Ho-Geun Yoon; Doug W Chan; Zhi-Qing Huang; Jiwen Li; Joseph D Fondell; Jun Qin; Jiemin Wong
Journal:  EMBO J       Date:  2003-03-17       Impact factor: 11.598

Review 2.  Co-repressors 2000.

Authors:  L J Burke; A Baniahmad
Journal:  FASEB J       Date:  2000-10       Impact factor: 5.191

3.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

4.  Reading and function of a histone code involved in targeting corepressor complexes for repression.

Authors:  Ho-Geun Yoon; Youngsok Choi; Philip A Cole; Jiemin Wong
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

5.  Recruitment of N-CoR/SMRT-TBLR1 corepressor complex by unliganded thyroid hormone receptor for gene repression during frog development.

Authors:  Akihiro Tomita; Daniel R Buchholz; Yun-Bo Shi
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

6.  TBLR1 regulates the expression of nuclear hormone receptor co-repressors.

Authors:  Xin-Min Zhang; Qing Chang; Lin Zeng; Judy Gu; Stuart Brown; Ross S Basch
Journal:  BMC Cell Biol       Date:  2006-08-07       Impact factor: 4.241

7.  The human ovarian surface epithelium is an androgen responsive tissue.

Authors:  R J Edmondson; J M Monaghan; B R Davies
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

8.  Transducin (β)-like 1 X-linked receptor 1 promotes proliferation and tumorigenicity in human breast cancer via activation of beta-catenin signaling.

Authors:  Xinghua Li; Weijiang Liang; Junling Liu; Chuyong Lin; Shu Wu; Libing Song; Zhongyu Yuan
Journal:  Breast Cancer Res       Date:  2014-10-24       Impact factor: 6.466

9.  A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors.

Authors:  Valentina Perissi; Aneel Aggarwal; Christopher K Glass; David W Rose; Michael G Rosenfeld
Journal:  Cell       Date:  2004-02-20       Impact factor: 41.582

10.  Cytoplasmic, full length and novel cleaved variant, TBLR1 reduces apoptosis in prostate cancer under androgen deprivation.

Authors:  Garrett Daniels; Xinmin Zhang; Xuelin Zhong; Larion Santiago; Ling Hang Wang; Xinyu Wu; Jack Y Zhang; Fengxia Liang; Xin Li; Thomas A Neubert; Laurey Steinke; Ying Shen; Ross Basch; Robert Schneider; David E Levy; Peng Lee
Journal:  Oncotarget       Date:  2016-06-28
View more
  5 in total

Review 1.  Research Progress of DUB Enzyme in Hepatocellular Carcinoma.

Authors:  Jie Zhao; Jinhui Guo; Yanan Wang; Qiancheng Ma; Yu Shi; Feng Cheng; Qiliang Lu; Wen Fu; Guangxiong Ouyang; Ji Zhang; Qiuran Xu; Xiaoge Hu
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

Review 2.  The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers.

Authors:  Zbyslaw Sondka; Sally Bamford; Charlotte G Cole; Sari A Ward; Ian Dunham; Simon A Forbes
Journal:  Nat Rev Cancer       Date:  2018-11       Impact factor: 60.716

3.  Transducin (β)-like 1 X-linked receptor 1 correlates with clinical prognosis and clinicopathological characteristics in human solid carcinomas.

Authors:  Fangteng Liu; Hui Gao; Yang Zhao; Zhengming Zhu
Journal:  Oncotarget       Date:  2017-06-27

4.  Correlations between TBL1XR1 and recurrence of colorectal cancer.

Authors:  Hongda Liu; Yunfei Xu; Qun Zhang; Kangshuai Li; Dawei Wang; Shuo Li; Shanglei Ning; Hui Yang; Weichen Shi; Zhaochen Liu; Yuxin Chen
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

5.  Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients - an immunohistochemical study.

Authors:  Asmaa Hussein Mohamed; Mariem A Elfeky; Shereen Elshorbagy; Nabila Hefzi; Tamer Oraby; Waleed A Abdelhady; Mahmoud Sharaf Eldein; Ahmed Embaby; Ehab M Oraby
Journal:  Contemp Oncol (Pozn)       Date:  2022-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.